(Q41261601)

28 September 2017

1 reference

title

Anti-leukotriene intervention: is there adequate information for clinical use in asthma? (English)

1 reference

28 September 2017

Ind PW

1

1 reference

28 September 2017

publication date

1 November 1996

1 reference

28 September 2017

1 reference

28 September 2017

volume

90

1 reference

28 September 2017

issue

10

1 reference

28 September 2017

page(s)

575-586

1 reference

Mucosal inflammation in asthma

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Leukotrienes are potent constrictors of human bronchi

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Effects of leukotriene D4 on mucociliary and respiratory function in allergic and nonallergic sheep.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Release of leukotrienes in patients with bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Recovery of Leukotriene E4from the Urine of Patients with Airway Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Clinical and Biochemical Effects of an Oral Leukotriene Biosynthesis Inhibitor (MK886) in Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

New perspectives on basic mechanisms in lung disease. 3. Drug intervention in asthma: present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

Treatment of childhood asthma for 13 months and longer with beclomethasone dipropionate aerosol

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990015-3

7 January 2021

10.1016/S0954-6111(96)90015-3

Identifiers

DOI

1 reference

28 September 2017

1 reference